US2019241582A1PendingUtilityA1
Triazole ACC inhibitors and uses thereof
Est. expiryNov 25, 2035(~9.4 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 31/04A61P 31/10A61P 33/00A61P 3/04C07D 495/04C12Y 604/01002A01N 43/90C07D 487/04C12N 9/93C07D 491/048
56
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides triazole compounds useful as inhibitors of Acetyl CoA Carboxylase (ACC), compositions thereof, and methods of using the same.
Claims
exact text as granted — not AI-modified1 . A compound of formula I:
or a pharmaceutically acceptable salt or agriculturally acceptable salt thereof, wherein:
X is —O—, —S—, or —NR—;
R 1 is hydrogen, C 1-4 aliphatic optionally substituted with 1-4 halogen, —OR, —SR, —N(R) 2 , —N(R)C(O)R, —C(O)N(R) 2 , —N(R)C(O)N(R) 2 , —N(R)C(O)OR, —OC(O)N(R) 2 , —N(R)S(O) 2 R, —S(O) 2 N(R) 2 , —C(O)R, —C(O)OR, —OC(O)R, —S(O)R, or —S(O) 2 R;
each instance of R 2 , R 6 , R 7 , and R 8 is independently oxo; halogen; —CN; —OR; —R a , —SR; —N(R) 2 ; —N(R)C(O)R; —C(O)N(R) 2 ; —N(R)C(O)N(R) 2 ; —N(R)C(O)OR; —OC(O)N(R) 2 ; —N(R)S(O) 2 R; —S(O) 2 N(R) 2 ; —C(O)R; —C(O)OR; —OC(O)R; —S(O)R; or —S(O) 2 R;
each R is independently hydrogen or R a ;
each R a is independently an optionally substituted group selected from C 1-6 aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
L 1 is a covalent bond; a 1-6 membered straight or branched bivalent hydrocarbon chain; cyclopropylenyl; cyclobutylenyl; or oxetanylenyl;
L 2 is a covalent bond or a 1-6 membered straight or branched bivalent hydrocarbon chain; wherein L 2 is substituted by n instances of R 9 ;
R 3 is —OR, —C(O)OR, —N(R)C(O)OR, —OC(O)N(R) 2 , —C(O)N(R)OR, —C(O)NH 2 , —C(O)NHR a , C(O)N(R a ) 2 , or —C(O)Hy;
Hy is a 3-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein Hy is substituted by p instances of R 6 ;
R 4 is selected from a 3-8 membered monocyclic saturated or partially unsaturated carbocyclic ring, a 4-8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein R 4 is substituted by q instances of R 7 ;
each R 5 is independently hydrogen, C 1-4 aliphatic, a 3-8 membered monocyclic saturated or partially unsaturated carbocyclic ring, a 4-8 membered monocyclic saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein each R 5 is substituted with r instances of R 8 ;
each R 9 is independently oxo or —OR 5 ;
m is 0, 1, 2, or 3;
n is 0, 1, or 2;
p is 0, 1, 2, 3, or 4;
q is 0, 1, 2, 3, 4, or 5; and
r is 0, 1, 2, 3, or 4.
2 .- 26 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.